Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Improving Vascular Function in Veterans With HFpEF
NCT06312748Phase 1Recruiting
- Sponsor
- VA Office of Research & Development
- Start
- May 2021
- Primary completion
- Sep 2028
- Modality
- Allosteric Modulators, Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, randomised trial of citrulline, sapropterin and atorvastatin in heart failure with preserved ejection fraction (HFpEF) (6 arms), sponsored by VA Office of Research & Development. Primary endpoint: Flow-mediated dilation at Day 90. Started May 2021; status: recruiting.
02
Drugs
citrullinesapropterinatorvastatin
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT06312748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06312748.